UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

UCSF has unveiled Nine Square Therapeutics with $50m in series A capital from founding investor Apple Tree Partners.

University of Oxford emeritus professor Gordon Clark will oversee IP Group's approach to ethical dealmaking and report to the firm's board of directors.

The ultrasound therapeutics developer, a University of Oxford spinout, has raised series B2 funding in the run-up to clinical testing of its cancer drug delivery platform.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Licence agreements at Satt Ouest Valorisation grew year-on-year despite the regional TTO’s patent portfolio shrinking with the disposal of 82 inventions.

Deep tech-focused commercialisation manager Olivia Nicoletti has departed Cambridge Enterprise for a senior role at Angel CoFund.